191 related articles for article (PubMed ID: 24068394)
1. High variability in MMP2/TIMP2 and MMP9/TIMP1 expression in secondary liver tumors.
Avădanei R; Căruntu ID; Amălinei C; Lozneanu L; Balan R; Grigoraş A; Ciobanu Apostol D; Giuşcă SE
Rom J Morphol Embryol; 2013; 54(3):479-85. PubMed ID: 24068394
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
[TBL] [Abstract][Full Text] [Related]
3. Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma.
Kunz P; Sähr H; Lehner B; Fischer C; Seebach E; Fellenberg J
BMC Cancer; 2016 Mar; 16():223. PubMed ID: 26979530
[TBL] [Abstract][Full Text] [Related]
4. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
[TBL] [Abstract][Full Text] [Related]
5. Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart.
Soini Y; Satta J; Määttä M; Autio-Harmainen H
J Pathol; 2001 Jun; 194(2):225-31. PubMed ID: 11400152
[TBL] [Abstract][Full Text] [Related]
6. Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover.
Phillips PA; McCarroll JA; Park S; Wu MJ; Pirola R; Korsten M; Wilson JS; Apte MV
Gut; 2003 Feb; 52(2):275-82. PubMed ID: 12524413
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study.
Pietruszewska W; Bojanowska-Poźniak K; Kobos J
Otolaryngol Pol; 2016 Jun; 70(3):32-43. PubMed ID: 27386931
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of reversion-inducing cysteine-rich protein with Kazal motifs in malignant melanoma: inverse correlation with membrane-type 1-matrix metalloproteinase and tissue inhibitor of metalloproteinase 2.
Jacomasso T; Trombetta-Lima M; Sogayar MC; Winnischofer SM
Melanoma Res; 2014 Feb; 24(1):32-9. PubMed ID: 24335752
[TBL] [Abstract][Full Text] [Related]
9. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
Staack A; Badendieck S; Schnorr D; Loening SA; Jung K
BMC Urol; 2006 Aug; 6():19. PubMed ID: 16901349
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor binding protein related protein 1 knockdown attenuates hepatic fibrosis via the regulation of MMPs/TIMPs in mice.
Ren JJ; Huang TJ; Zhang QQ; Zhang HY; Guo XH; Fan HQ; Li RK; Liu LX
Hepatobiliary Pancreat Dis Int; 2019 Feb; 18(1):38-47. PubMed ID: 30243878
[TBL] [Abstract][Full Text] [Related]
11. MMP/TIMP imbalance in amniotic fluid during PROM: an indirect support for endogenous pathway to membrane rupture.
Fortunato SJ; Menon R; Lombardi SJ
J Perinat Med; 1999; 27(5):362-8. PubMed ID: 10642956
[TBL] [Abstract][Full Text] [Related]
12. The Influence of Simvastatin on NGAL, Matrix Metalloproteinases and Their Tissue Inhibitors in Human Intraluminal Thrombus and Abdominal Aortic Aneurysm Tissue.
Piechota-Polanczyk A; Demyanets S; Mittlboeck M; Hofmann M; Domenig CM; Neumayer C; Wojta J; Klinger M; Nanobachvili J; Huk I
Eur J Vasc Endovasc Surg; 2015 May; 49(5):549-55. PubMed ID: 25800096
[TBL] [Abstract][Full Text] [Related]
13. Gelatinase expression and proteolytic activity in giant-cell arteritis.
Segarra M; García-Martínez A; Sánchez M; Hernández-Rodríguez J; Lozano E; Grau JM; Cid MC
Ann Rheum Dis; 2007 Nov; 66(11):1429-35. PubMed ID: 17502363
[TBL] [Abstract][Full Text] [Related]
14. Heavy smoking before coronary surgical procedures affects the native matrix metalloproteinase-2 and matrix metalloproteinase-9 gene expression in saphenous vein conduits.
Yongxin S; Wenjun D; Qiang W; Yunqing S; Liming Z; Chunsheng W
Ann Thorac Surg; 2013 Jan; 95(1):55-61. PubMed ID: 23146278
[TBL] [Abstract][Full Text] [Related]
15. [Effect of 90 percentage portal branch ligation on liver regeneration and expression of metalloproteinase and tissue inhibitors of metalloproteinases in rats].
Li KZ; Yao YT; Luo L; Zhang X; Rong C; Luo ZL; Yan HT; Zhu YQ; Tian FZ
Zhonghua Gan Zang Bing Za Zhi; 2010 May; 18(5):374-8. PubMed ID: 20510005
[TBL] [Abstract][Full Text] [Related]
16. Positive correlations between circulating adiponectin and MMP2 in preeclampsia pregnant.
Eleuterio NM; Palei AC; Rangel Machado JS; Tanus-Santos JE; Cavalli RC; Sandrim VC
Pregnancy Hypertens; 2015 Apr; 5(2):205-8. PubMed ID: 25943646
[TBL] [Abstract][Full Text] [Related]
17. mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor.
Scrideli CA; Cortez MA; Yunes JA; Queiróz RG; Valera ET; da Mata JF; Toledo SR; Pavoni-Ferreira P; Lee ML; Petrilli AS; Brandalise SR; Tone LG
Leuk Res; 2010 Jan; 34(1):32-7. PubMed ID: 19875168
[TBL] [Abstract][Full Text] [Related]
18. Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases.
Gentner B; Wein A; Croner RS; Zeittraeger I; Wirtz RM; Roedel F; Dimmler A; Dorlaque L; Hohenberger W; Hahn EG; Brueckl WM
Anticancer Res; 2009 Jan; 29(1):67-74. PubMed ID: 19331134
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer.
Ross JS; Kaur P; Sheehan CE; Fisher HA; Kaufman RA; Kallakury BV
Mod Pathol; 2003 Mar; 16(3):198-205. PubMed ID: 12640098
[TBL] [Abstract][Full Text] [Related]
20. Is determination of matrix metalloproteinases and their tissue inhibitors serum concentrations useful in patients with gastroenteropancreatic and bronchopulmonary neuroendocrine neoplasms?
Blicharz-Dorniak J; Kos-Kudła B; Foltyn W; Kajdaniuk D; Marek B; Zemczak A; Strzelczyk J
Endokrynol Pol; 2012; 63(6):470-6. PubMed ID: 23339005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
